Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Rebif 22microg/0.5ml inj and Rebif 8.8microg/0.2ml inj pfs
0802040M0BBAFAI
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 22micrograms/0.5ml (6million units) inj 1.5ml cart
0802040M0BBAGAJ
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 22micrograms/0.5ml (6million units) inj pfs
0802040M0BBADAF
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 44micrograms/0.5ml (12million units) inj 1.5ml cart
0802040M0BBAHAK
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 44micrograms/0.5ml (12million units) inj pf pens
0802040M0BBAKAN
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 44micrograms/0.5ml (12million units) inj pfs
0802040M0BBAEAG
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 8.8microg/0.1ml with 22microg/0.25ml initiation pack
0802040M0BBAIAL
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Recivit 133microgram sublingual tablets
0407020A0BTAABX
|
Recivit | Fentanyl | Central Nervous System | No data available |
|
Recivit 267microgram sublingual tablets
0407020A0BTADBZ
|
Recivit | Fentanyl | Central Nervous System | No data available |
|
Recivit 400microgram sublingual tablets
0407020A0BTABAZ
|
Recivit | Fentanyl | Central Nervous System | No data available |
|
Recivit 533microgram sublingual tablets
0407020A0BTACBY
|
Recivit | Fentanyl | Central Nervous System | No data available |
|
Recivit 800microgram sublingual tablets
0407020A0BTAEBB
|
Recivit | Fentanyl | Central Nervous System | No data available |
|
Recombinate 1,000unit inj vials
0211000I0BFABAH
|
Recombinate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Recombinate 500unit inj vials
0211000I0BFAAAG
|
Recombinate | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Reconvan liquid
0914071E0BBAAAA
|
Reconvan tube feed non ACBS 1kcal/ml h/prot for use in IC | Tube feed non ACBS 1kcal/ml h/prot for use in IC (0914071) | Nutrition and Blood | No data available |
|
Red Clover flower tincture
190606000BCVFA0
|
Proprietary compound preparation BNF 1906060 | Other tincture preparations | Other Drugs and Preparations | No data available |
|
Redifit belt flange 25mm
23555855540
|
Redifit belt flange 25mm | Flanges | Stoma Appliances | No data available |
|
Redifit belt flange 32mm
23555855541
|
Redifit belt flange 32mm | Flanges | Stoma Appliances | No data available |
|
Redifit belt flange 38mm
23555855542
|
Redifit belt flange 38mm | Flanges | Stoma Appliances | No data available |
|
Redifit belt flange 44mm
23555855543
|
Redifit belt flange 44mm | Flanges | Stoma Appliances | No data available |
|
Redifit belt flange 51mm
23555855544
|
Redifit belt flange 51mm | Flanges | Stoma Appliances | No data available |
|
Redifit belt flange 64mm
23555855545
|
Redifit belt flange 64mm | Flanges | Stoma Appliances | No data available |
|
Redifit belt flange 75mm
23555855546
|
Redifit belt flange 75mm | Flanges | Stoma Appliances | No data available |
|
Redifit colostomy bag
23355853516
|
Redifit colostomy bag | Colostomy Bags | Stoma Appliances | No data available |
|
Redifit colostomy bag with karaya seal 32mm opaque
23355853501
|
Redifit colostomy bag with karaya seal 32mm opaque | Colostomy Bags | Stoma Appliances | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.